Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIC HARRIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1902068158
CMS profile
1072128
Location
DAYTONA BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,886.44

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,635.79 151
Long term medical supply or device loan $166.66 2
Education $83.99 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIC HARRIS

NPI 1902068158 · CMS profile ID 1072128

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DAYTONA BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902068158?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIC HARRIS, NPI 1902068158, CMS profile ID 1072128. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902068158?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ERIC HARRIS, NPI 1902068158, CMS profile ID 1072128. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902068158?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ERIC HARRIS, NPI 1902068158, CMS profile ID 1072128, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1902068158?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $2,886.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–154 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $17.7401/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992316699 CMS
Amgen Inc. $13.9301/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020574931 CMS
Alexion Pharmaceuticals, Inc. $13.8701/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017084835 CMS
Gilead Sciences, Inc. $16.5201/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025945677 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,931.97 186
PY2020 $13,711.65 56
PY2021 $22,819.73 30
PY2022 $8,655.74 92
PY2023 $2,886.44 154
PY2024 $2,664.30 135
PY2025 $3,298.19 135

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $410,930.93 27
PY2024 Principal investigator $136,923.17 6
PY2023 Principal investigator $155,405.02 56
PY2022 Principal investigator $101,696.25 37
PY2021 Principal investigator $120,951.45 53
PY2020 Principal investigator $138,401.05 33
PY2019 Principal investigator $10,486.75 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $22,700.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187882694
Principal investigator 1 Genentech, Inc. $2,025.50 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211649116
Principal investigator 1 Genentech, Inc. $169.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211649109
Principal investigator 1 Genentech, Inc. $1,963.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211649112
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,749.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1235993909
Principal investigator 1 Eli Lilly and Company $541.09 10/27/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187881180
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,262.50 07/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185545743
Principal investigator 1 Genentech, Inc. $728.00 07/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211649090
Principal investigator 1 Genentech, Inc. $142.00 07/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211649101
Principal investigator 1 Genentech, Inc. $12,751.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211649106
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,767.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185545735
Principal investigator 1 Genentech, Inc. $2,345.00 07/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211649097
Principal investigator 1 Genentech, Inc. $146.00 07/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211649095
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $824.70 06/24/2025 Non-covered Recipient Entity
Florida Cancer Specialists
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1235997359
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,800.00 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185545733
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,965.76 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185545737
Principal investigator 1 BeiGene, Ltd. $84.20 05/19/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190325072
Principal investigator 1 Celgene Corporation $7,083.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1222306687
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185545731
Principal investigator 1 AstraZeneca Pharmaceuticals LP $99,562.89 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185545739
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,250.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185545741
Principal investigator 1 Merck Sharp & Dohme LLC $8,280.00 04/14/2025 Non-covered Recipient Entity
FCS Research East
A Phase 2, Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation No dispute reported 06/30/2026 1232936220
Principal investigator 1 Mirati Therapeutics, Inc. $9,534.00 04/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy No dispute reported 06/30/2026 1236530664
Principal investigator 1 Celgene Corporation $54,776.33 02/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1222305652
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,122.84 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185545747
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,400.00 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185545745
Principal investigator 1 Mirati Therapeutics, Inc. $22,958.12 01/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) No dispute reported 06/30/2026 1236530659